Article Abstract

Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment

Authors: Silvia Vecchiarelli, Lorenza Landi, Federico Cappuzzo

Abstract

Lung cancer is the first cause of cancer deaths worldwide (1). Nowadays, treatment landscape of non-small cell lung cancer (NSCLC) is rapidly changing by the introduction of immune-checkpoint inhibitors (2,3).